StreetInsider.com News Articles

NewAmsterdam Pharma Co NV (NAMS) Reiterated at Buy by Stifel

Tue, 08 Sep 2026 06:55:36 -0400

Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).

The analyst commented, "NVS announced HORIZON failed. There was healthy skepticism after repeated delays--and it's a big reason for NAMS' weakness. Even still, it's a disappointment--that said, our view is: (1) the read-through/implications for PREVAIL are very nuanced; and (2) we don't need to believe much--or anything--from Lp(a) to have confidence in obicetrapib. HORIZON may not have been the best test of the Lp(a) hypothesis, while the populations are entirely different (HORIZON had well-controlled LDL-C--probably why events were low). Moreover--PREVAIL's baseline Lp(a)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:01:00 -0400

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 38,900 of NewAmsterdam’s ordinary shares to five non-executive new hires, as well as inducement share options covering 14,000 ordinary shares to

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:01:00 -0400

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head

NewAmsterdam Pharma (NAMS) call put ratio 1 call to 1 put on 3900 contracts

Mon, 31 Aug 2026 05:32:09 -0400

NewAmsterdam Pharma (NASDAQ: NAMS) 30-day option implied volatility is at 89; compared to its 52-week of 58 to 113. Call put ratio 1 call to 1 put on 3900 contracts.

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Wed, 26 Aug 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.

Presentation details are as follows:

Title: Determinants of Short Term

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Wed, 26 Aug 2026 08:00:00 -0400

Presentation details are as follows:

Title: Determinants of Short Term

Form 4 NewAmsterdam Pharma Co For: Aug 24 Filed by: Kastelein Johannes Jacob Pieter

Tue, 25 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260825/26975145.html

Form 4 NewAmsterdam Pharma Co For: Aug 24 Filed by: Kastelein Johannes Jacob Pieter

Tue, 25 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260825/26975145.html

Form 3 NewAmsterdam Pharma Co For: Aug 10 Filed by: Gunning Robert William

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930427.html

Form 3 NewAmsterdam Pharma Co For: Aug 10 Filed by: Gunning Robert William

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930427.html

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:01:00 -0400

NAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 28,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:01:00 -0400

NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $50 at RBC Capital

Thu, 06 Aug 2026 06:52:44 -0400

RBC Capital analyst Leonid Timashev lowered the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) to $50.00 (from $51.00) while maintaining a Outperform rating.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Wed, 05 Aug 2026 07:00:00 -0400

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Topline data from RUBENS Phase 3 expected by year-end 2026 –

– $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 –

– Company to host investor day today at 9:00 AM ET in New York City –

NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Wed, 05 Aug 2026 07:00:00 -0400

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Topline data from RUBENS Phase 3 expected by year-end 2026 –

– $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 –

– Company to host investor day today at 9:00 AM ET in New York City –

NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

Wed, 29 Jul 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City.

Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer; John

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

Wed, 29 Jul 2026 08:00:00 -0400

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City.

Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer; John

EU panel backs NewAmsterdam and Menarini cholesterol drugs

Fri, 24 Jul 2026 08:00:14 -0400

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for two obicetrapib-based treatments developed by NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) and its partner Menarini Group.

The recommendation covers Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolemia, including heterozygous familial and non-familial forms, as well as mixed dyslipidemia.

The CHMP opinion is supported by data from the Phase 3 BROADWAY, BROOKLYN, and TANDEM trials. Those studies showed LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo,

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co

Fri, 24 Jul 2026 08:00:00 -0400

- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe -

- Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data -

- European Commission decision expected in 2H26 -

NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, July 24, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co

Fri, 24 Jul 2026 08:00:00 -0400

- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe -

- Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data -

- European Commission decision expected in 2H26 -

NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, July 24, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not

Form 4 NewAmsterdam Pharma Co For: Jul 20 Filed by: Kooij Louise Frederika

Wed, 22 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260722/26801626.html

Form 4 NewAmsterdam Pharma Co For: Jul 20 Filed by: Kooij Louise Frederika

Wed, 22 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260722/26801626.html

BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform

Mon, 20 Jul 2026 16:36:54 -0400

BMO Capital initiates coverage on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) with a Outperform rating and a price target of $58.00.
For an analyst ratings summary and ratings history on NewAmsterdam Pharma Co NV click here. For more ratings news on NewAmsterdam Pharma Co NV click here.
Shares of NewAmsterdam Pharma Co NV closed at $31.68 yesterday.